scholarly journals Surgical treatment of severe ventricular septal defects complicated with patent ductus arteriosus in infancy

1978 ◽  
Vol 8 (2) ◽  
pp. 136-137
Author(s):  
K. Koyamada
Keyword(s):  
Surgical Treatment ◽  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Ventricular Septal Defects ◽  
Septal Defects ◽  
Patent Ductus

Transcatheter closure of ventricular septal defect with Occlutech Duct Occluder

2018 ◽  
Vol 28 (4) ◽  
pp. 598-601 ◽  
Author(s):  
Sezen Atik-Ugan ◽  
Irfan Levent Saltik
Keyword(s):  
Ventricular Septal Defect ◽  
Patent Ductus Arteriosus ◽  
Septal Defect ◽  
Transcatheter Closure ◽  
Ductus Arteriosus ◽  
Ventricular Septal Defects ◽  
Septal Defects ◽  
Patent Ductus

AbstractPatent ductus arteriosus occluders are used for transcatheter closure of ventricular septal defects, as well as for closure of patent ductus arteriosus. The Occlutech Duct Occluder is a newly introduced device for transcatheter closure of patent ductus arteriosus. Here, we present a case in which the Occlutech Duct Occluder was successfully used on a patient for the closure of a perimembraneous ventricular septal defect.

Transcatheter closure of perimembranous ventricular septal defects with ductal occluders

2014 ◽  
Vol 25 (5) ◽  
pp. 918-926 ◽  
Author(s):  
Jayaranganath Mahimarangaiah ◽  
Anand Subramanian ◽  
Srinivasa Kikkeri Hemannasetty ◽  
Subhash Chandra ◽  
Satish Karur ◽  
...  
Keyword(s):  
Patent Ductus Arteriosus ◽  
Tricuspid Regurgitation ◽  
Heart Block ◽  
Complete Heart Block ◽  
Ductus Arteriosus ◽  
Amplatzer Duct Occluder ◽  
Ventricular Septal Defects ◽  
Septal Defects ◽  
Patent Ductus ◽  
New Onset

AbstractBackground: To study the feasibility and complications associated with the use of ductal occluders for closure of perimembranous ventricular septal defects. Methods: A total of 126 patients, ranging from 1 to 41 years of age (median – 8 years), underwent closure of ventricular septal defects from August 2010 to April 2013. Small- and moderate-sized defects were closed using first-generation Patent ductus arteriosus occluders or Amplatzer Duct Occluder-II. Patients were followed up for the development of complications such as heart block, aortic regurgitation, and tricuspid regurgitation. Results: Patent ductus arteriosus occluders were used in 81 patients, and the Amplatzer Duct Occluder-II device in 45 patients. The devices were successfully deployed in 99.2% of the cases. One patient had embolisation of an Amplatzer Duct Occluder-II device soon after deployment. There was one case of transient complete heart block (0.8%) needing temporary pacing, and two cases of isoarrhythmic atrioventricular dissociation (1.6%). One patient developed late-onset complete heart block 15 months after the procedure and underwent permanent pacemaker implantation. There were no instances of new-onset aortic regurgitation. New-onset mild tricuspid regurgitation was seen in two patients. Of the patients, three had small residual shunts on follow-up, without haemolysis. Conclusions: Duct occluders can be used to effectively close small- and moderate-sized ventricular septal defects. The incidence of complete heart block and valvular regurgitations are much less than reported with other devices, and they are cost-effective.

Sign in / Sign up

Export Citation Format

Share Document